v3.26.1
Collaborations and Other Arrangements (Details)
$ in Millions, $ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 23, 2021
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2026
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2024
CAD ($)
Dec. 31, 2025
USD ($)
Junshi Biosciences            
Collaborative Arrangements And Noncollaborative Arrangement Transactions            
Royalties due     $ 2.7     $ 4.7
Canada license agreement with Apotex            
Collaborative Arrangements And Noncollaborative Arrangement Transactions            
Company an upfront payment received       $ 6.3    
Regulatory and sales milestones eligible to receive         $ 51.5  
Collaboration agreement, royalty on net sales, percentage       20.00% 20.00%  
Renewal term     10 years      
Vaccinex License Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions            
Accrued milestone payment           $ 1.0
Maximum aggregate milestone payments to be made $ 2.0          
Maximum aggregate amount payable for achievement of certain clinical milestones low single digit royalties on global net sales of any approved licensed products $ 11.5          
Clinical milestone payments   $ 1.0